Ascendis Pharma As Stock Performance
| ASND Stock | USD 169.90 7.30 4.12% |
Ascendis Pharma has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.26, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Ascendis Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Ascendis Pharma is expected to be smaller as well. Ascendis Pharma AS right now shows a risk of 2.32%. Please confirm Ascendis Pharma AS value at risk, daily balance of power, and the relationship between the total risk alpha and expected short fall , to decide if Ascendis Pharma AS will be following its price patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ascendis Pharma AS are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating basic indicators, Ascendis Pharma may actually be approaching a critical reversion point that can send shares even higher in August 2025. ...more
Actual Historical Performance (%)
One Day Return (4.12) | Five Day Return (3.19) | Year To Date Return 23.12 | Ten Year Return 692.81 | All Time Return 802.28 |
1 | Ascendis Pharma First Quarter 2025 Earnings Revenues Beat Expectations, EPS Lags | 05/06/2025 |
2 | Optimistic Outlook for Ascendis Pharma Buy Rating Driven by COACH Phase 2 Trial and Yorvipath Launch - TipRanks | 05/22/2025 |
3 | Ascendis Pharma Reveals Promising Interim Results from COACH Trial ASND Stock News | 06/09/2025 |
4 | Ascendis Pharma Rated as a Hold at Cannacord Genuity on Growth Hormone Prospects | 06/17/2025 |
5 | Summit Therapeutics Signs Sublease with Ascendis Pharma - TipRanks | 06/20/2025 |
6 | Peering Into Ascendis Pharmas Recent Short Interest | 07/03/2025 |
7 | 100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today | 07/07/2025 |
8 | Ascendis Pharma Sees Price Target Raised by Citigroup ASND Stock News | 07/11/2025 |
9 | Ascendis Pharma Reports Promising Long-Term Results for TransCon PTH | 07/14/2025 |
10 | Wall Street Analysts Believe Ascendis Pharma Could Rally 29.83 percent Heres is How to Trade | 07/16/2025 |
| Begin Period Cash Flow | 392.2 M | |
| Total Cashflows From Investing Activities | 6.9 M | |
| Free Cash Flow | -307.6 M |
Ascendis Pharma Relative Risk vs. Return Landscape
If you would invest 16,115 in Ascendis Pharma AS on April 20, 2025 and sell it today you would earn a total of 875.00 from holding Ascendis Pharma AS or generate 5.43% return on investment over 90 days. Ascendis Pharma AS is currently generating 0.1116% in daily expected returns and assumes 2.3182% risk (volatility on return distribution) over the 90 days horizon. In different words, 20% of stocks are less volatile than Ascendis, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ascendis Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ascendis Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Ascendis Pharma AS, and traders can use it to determine the average amount a Ascendis Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0481
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ASND | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.32 actual daily | 20 80% of assets are more volatile |
Expected Return
| 0.11 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Ascendis Pharma is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Ascendis Pharma by adding it to a well-diversified portfolio.
Ascendis Pharma Fundamentals Growth
Ascendis Stock prices reflect investors' perceptions of the future prospects and financial health of Ascendis Pharma, and Ascendis Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ascendis Stock performance.
| Return On Equity | -8.18 | ||||
| Return On Asset | -0.22 | ||||
| Profit Margin | (0.93) % | ||||
| Operating Margin | (1.03) % | ||||
| Current Valuation | 10.66 B | ||||
| Shares Outstanding | 60.49 M | ||||
| Price To Earning | (9.10) X | ||||
| Price To Book | 14.55 X | ||||
| Price To Sales | 27.88 X | ||||
| Revenue | 363.64 M | ||||
| Gross Profit | 314.5 M | ||||
| EBITDA | (290.02 M) | ||||
| Net Income | (378.08 M) | ||||
| Cash And Equivalents | 955.15 M | ||||
| Cash Per Share | 17.11 X | ||||
| Total Debt | 856.62 M | ||||
| Debt To Equity | 0.84 % | ||||
| Current Ratio | 9.66 X | ||||
| Book Value Per Share | (3.14) X | ||||
| Cash Flow From Operations | (306.2 M) | ||||
| Earnings Per Share | (6.80) X | ||||
| Market Capitalization | 10.28 B | ||||
| Total Asset | 1.18 B | ||||
| Retained Earnings | (2.28 B) | ||||
| Working Capital | 153 M | ||||
| Current Asset | 125.65 M | ||||
| Current Liabilities | 11.45 M | ||||
About Ascendis Pharma Performance
By analyzing Ascendis Pharma's fundamental ratios, stakeholders can gain valuable insights into Ascendis Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ascendis Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ascendis Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.4 K | 4.4 K | |
| Return On Tangible Assets | (0.32) | (0.34) | |
| Return On Capital Employed | (1.03) | (0.97) | |
| Return On Assets | (0.32) | (0.34) | |
| Return On Equity | 3.58 | 3.76 |
Things to note about Ascendis Pharma AS performance evaluation
Checking the ongoing alerts about Ascendis Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ascendis Pharma AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 363.64 M. Net Loss for the year was (378.08 M) with profit before overhead, payroll, taxes, and interest of 314.5 M. | |
| Ascendis Pharma AS currently holds about 955.15 M in cash with (306.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 17.11. | |
| Ascendis Pharma AS has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from zacks.com: Wall Street Analysts Believe Ascendis Pharma Could Rally 29.83 percent Heres is How to Trade |
- Analyzing Ascendis Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ascendis Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Ascendis Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ascendis Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ascendis Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ascendis Pharma's stock. These opinions can provide insight into Ascendis Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ascendis Stock analysis
When running Ascendis Pharma's price analysis, check to measure Ascendis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ascendis Pharma is operating at the current time. Most of Ascendis Pharma's value examination focuses on studying past and present price action to predict the probability of Ascendis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ascendis Pharma's price. Additionally, you may evaluate how the addition of Ascendis Pharma to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |